TY  - JOUR
AU  - Pérez-Ramírez, Cristina
AU  - Cañadas-Garre, Marisa
AU  - Alnatsha, Ahmed
AU  - Molina, Miguel Ángel
AU  - Robles, Ana I
AU  - Villar, Eduardo
AU  - Delgado, Juan Ramón
AU  - Faus-Dáder, María José
AU  - Calleja-Hernández, Miguel Ángel
PY  - 2017
DO  - 10.1016/j.suronc.2017.05.004
UR  - http://hdl.handle.net/10668/11500
T2  - Surgical oncology
AB  - Surgery is the standard treatment for early-stage NSCLC, and platinum-based chemotherapy remains as the treatment of choice for advanced-stage NSCLC patients with naïve EGFR status. However, overall 5-years relative survival rates are low....
LA  - en
KW  - Interleukins
KW  - Non-small cell lung cancer
KW  - Platinum based chemotherapy
KW  - Polymorphisms
KW  - Survival
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease Progression
KW  - Early Detection of Cancer
KW  - Female
KW  - Genetic Markers
KW  - Genotype
KW  - Humans
KW  - Interleukin-12 Subunit p35
KW  - Interleukin-16
KW  - Interleukins
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Polymorphism, Genetic
KW  - Prognosis
KW  - Prospective Studies
TI  - Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer.
TY  - research article
VL  - 26
ER  -